

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 October 2002 (03.10.2002)

PCT

(10) International Publication Number
WO 02/077168 A2

(51) International Patent Classification⁷: C12N
(21) International Application Number: PCT/US02/08413
(22) International Filing Date: 19 March 2002 (19.03.2002)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/278,061 22 March 2001 (22.03.2001) US

126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
MARSH, Donald, J. [US/US]; 126 East Lincoln Avenue,
Rahway, NJ 07065-0907 (US).

(74) Common Representative: MERCK & CO., INC.; 126
East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

Published:

— without international search report and to be republished
upon receipt of that report


(71) Applicant (for all designated States except US): MERCK
& CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway,
NJ 07065-0907 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): QIAN, Su [US/US];

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MCHIR DEFICIENT MICE



(57) Abstract: The present invention features viable MCHIR deficient mice. MCHIR deficient mice contain an alteration in one or both MCHIR alleles that substantially reduces expression of a functional MCHIR from the altered allele. Preferably, MCHIR deficient mice are MCHIR^{-/-} knockout mice.

BEST AVAILABLE COPY

WO 02/077168 A2

TITLE OF THE INVENTION
MCHIR DEFICIENT MICE

CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 The present application claims priority to provisional application U.S. Serial No. 60/278,061, filed March 22, 2001, hereby incorporated by reference herein.

BACKGROUND OF THE INVENTION

- 10 The references cited in the present application are not admitted to be prior art to the claimed invention.

 Neuropeptides present in the hypothalamus play a major role in mediating the control of body weight. (Flier, *et al.*, 1998. *Cell*, 92, 437-440.) Melanin-concentrating hormone (MCH) is a cyclic 19-amino acid neuropeptide synthesized as part of a larger pre-prohormone precursor in the hypothalamus which
15 also encodes neuropeptides NEI and NGE. (Nahon, *et al.*, 1990. *Mol. Endocrinol.* 4, 632-637.) MCH was first identified in salmon pituitary, and in fish MCH affects melanin aggregation thus affecting skin pigmentation. In trout and in cels MCH has also been shown to be involved in stress induced or CRF-stimulated ACTH release. (Kawauchi, *et al.*, 1983. *Nature* 305, 321-323.)

- 20 In humans two genes encoding MCH have been identified that are expressed in the brain. (Breton, *et al.*, 1993. *Mol. Brain Res.* 18, 297-310.) In mammals MCH has been localized primarily to neuronal cell bodies of the hypothalamus which are implicated in the control of food intake, including perikarya of the lateral hypothalamus and zona inertia. (Knigge, *et al.*, 1996. *Peptides* 17, 1063-
25 1073.)

 Pharmacological and genetic evidence suggest that the primary mode of MCH action is to promote feeding (orexigenic). MCH mRNA is up regulated in fasted mice and rats and in the *ob/ob* mouse. (Qu, *et al.*, 1996. *Nature* 380, 243-247.) Injection of MCH centrally (ICV) stimulates food intake and MCH antagonizes the
30 hypophagic effects seen with α melanocyte stimulating hormone (α MSH). (Qu, *et al.*, 1996. *Nature* 380, 243-247.) MCH deficient mice are lean, hypophagic and have increased metabolic rate. (Shimada, *et al.*, 1998. *Nature* 396, 670-673.) Transgenic mice overexpressing MCH are hyperphagic and develop insulin resistance and mild obesity. (Ludwig, *et al.*, 2001. *J. Clin. Invest.* 107, 379-386.)

MCH action is not limited to modulation of food intake as effects on the hypothalamic-pituitary-axis have been reported. (Nahon, 1994. *Critical Rev. in Neurobiol.* 8, 221-262.) MCH can modulate stress-induced release of ACTH. (Nahon, 1994. *Critical Rev. in Neurobiol.* 8, 221-262.)

- 5 Several references describe a receptor that is indicated to bind MCH ("MCH1R"). (Chambers, *et al.*, 1999. *Nature* 400, 261-265, Saito, *et al.*, 1999. *Nature* 400, 265-269, Bächner, *et al.*, 1999. *FEBS Letters* 457:522-524, Shimomura, *et al.*, 1999. *Biochemical and Biophysical Research Communications* 261, 622-626.)

10 SUMMARY OF THE INVENTION

The present invention features viable MCH1R deficient mice. MCH1R deficient mice contain an alteration in one or both MCH1R alleles that substantially reduces expression of a functional MCH1R from the altered allele. Preferably, MCH1R deficient mice are MCH1R -/- knockout mice.

- 15 An alteration that "substantially reduces expression" of a functional MCH1R is either (1) an alteration that results in no active MCH1R being produced from the altered allele or (2) an alteration that results in a MCH1R deficient mouse having one or more phenotypes associated with an MCH1R -/- knockout mouse, when the alteration is present in both alleles. Alterations substantially reducing expression of a functional MCH1R include alterations that result in little or no MCH1R
20 expression and alterations producing a MCH1R derivative which is expressed but contains little or no activity.

- Phenotypes associated with a MCH1R -/- knockout mouse include: reduced fat mass, increased food consumption when mice are maintained on regular
25 chow, hyperactivity, neuroendocrine abnormalities, increased energy expenditure as measured by indirect calorimetry, reduced respiratory quotient as measured by indirect calorimetry, decreased sensitivity to diet-induced obesity, resistance to the orexigenic effects of intracerebroventricular administration of MCH and resistance to the anorectic effects of intracerebroventricular administration a peptide antagonist of
30 MCH1R.

Thus, a first aspect of the present invention describes a MCH1R deficient mouse whose genome comprises an alteration in one or both MCH1R alleles. The alteration substantially reduces expression of a functional MCH1R from the altered allele.

Another aspect of the present invention describes a method of producing a MCH1R deficient mouse comprising an alteration of a MCH1R allele. The method comprises the steps of:

- (a) altering a MCH1R allele in a mouse embryonic stem cell by homologous recombination with a transgene to produce an altered embryonic stem cell;
- (b) introducing the altered embryonic stem cell into a mouse blastocyst to produce an altered blastocyst;
- (c) introducing the altered blastocyst into a pseudopregnant mouse to produce a pregnant mouse;
- (d) allowing the pregnant mouse to produce offspring; and
- (e) screening the offspring for the presence of an altered MCH1R allele to identify an MCH1R deficient mouse.

- Another aspect of the present invention describes a method of producing a MCH1R deficient mouse comprising an altered MCH1R in both alleles. The method comprises the steps of: (a) breeding two mice each comprising an alteration of the MCH1R in one allele to produce offspring; and (b) screening the offspring for the presence of an altered MCH1R in both alleles.

- Another aspect of the present invention describes a method of measuring the affect of a compound on a MCH1R deficient mouse. The method involves the steps of providing the compound to the MCH1R deficient mouse, and measuring one or more phenotypes associated with MCH1R activity.

- Another aspect of the present invention describes a method of screening for a compound to affect food intake, metabolism, stress, anxiety, fatigue, locomotor activity, circadian rhythm, or sleep. The method comprises identifying an MCH1R active compound able to modulate MCH1R activity using an *in vitro* assay; and measuring the ability of the MCH1R active compound on food intake, metabolism, stress, anxiety, fatigue, locomotor activity, circadian rhythm, or sleep.

- Other features and advantages of the present invention are apparent from the additional descriptions provided herein including the different examples. The provided examples illustrate different components and methodology useful in practicing the present invention. The examples do not limit the claimed invention. Based on the present disclosure the skilled artisan can identify and employ other components and methodology useful for practicing the present invention.

BRIEF DESCRIPTION OF THE DRAWING

Figure 1. Strategy employed for disrupting the MCH1R gene. "TK" refers to a HSV-thymidine kinase gene. "PGKneo" refers to a neomycin resistance gene.

5 Figure 2. DEXA analysis of 5-7-month-old group-housed male and female MCH1R $+/+$ (white bars), MCH1R $+/-$ (hatched bars) and MCH1R $-/-$ (shaded bars; $n = 12-14$ per group) littermate mice. All P values are from comparisons between MCH1R $+/+$ and MCH1R $-/-$ littermates. $^{**}P < 0.01$, $^{*}P < 0.05$.

10 Figure 3. Metabolic rate of ~8-week-old individually-housed male MCH1R $+/+$ ($n = 10$; filled squares) and MCH1R $-/-$ ($n = 13$; open circles) littermates. From 10 PM to 5 AM, the MCH1R $-/-$ curve was significantly different ($P < 0.05$) from the MCH1R $+/+$ curve. The solid horizontal bar represents the dark phases of the study.

15 Figure 4. Respiratory quotient (RQ) of mice in Figure 3. The MCH1R $-/-$ curve was significantly different ($P < 0.01$) from the MCH1R $+/+$ curve for the entire light phase. The solid horizontal bar represents the dark phases of the study.

20 Figure 5. Cumulative body weight gains of female wild-type ($Mchl1r^{+/+}$) and $Mchl1r^{-/-}$ littermates maintained simultaneously on either a regular chow diet (RC) or a high fat diet (HF) for 7 weeks ($n = 9-12$ per group). All groups were weight matched and all mice were 6-8-weeks-old at the initiation of the study.

25 Figure 6. Cumulative food intake by mice in Figure 5 during the 7-week period ($n = 9-11$ per group). P values are from comparisons between chow and high fat groups of the same genotype (*) or between $Mchl1r^{+/+}$ and $Mchl1r^{-/-}$ littermates maintained on the same diet (**). $^{*}P < 0.05$, $^{**}P < 0.001$.

30 Figure 7. Effect of chronic MCH infusion on daily food intake. Male 11-13-week-old MCH1R $+/+$ (squares) and MCH1R $-/-$ (circles) littermates received chronic dorsal third ventricle infusions of either MCH (~12 nmole/mouse/day; filled symbols) or vehicle (open symbols) for 6 days ($n = 9-11$ per group). Mice were cannulated and implanted with osmotic pumps containing only vehicle on day -5. On day 0, original pumps were replaced with new pumps containing either vehicle or MCH dissolved in vehicle. Beginning on day 1, all mice were maintained on a moderate fat diet. From days 1 to 6, the MCH1R $+/+$, MCH-treatment curve was significantly different ($P < 0.005$) from the three other curves.

Figure 8. Effect of chronic MCH infusion on cumulative body weight gain. Body weights of mice in Figure 7 were measured daily and values from day -4 were used to calculate cumulative body weight gains. From days 1 to 6, the MCHIR +/+, MCH-treatment curve was significantly different ($P < 0.0001$) from the three other curves.

Figure 9. Effect of chronic MCH infusion on body composition. DEXA analysis of body composition was performed on mice in Figure 7 at the end of the 6-day chronic infusion period MCHIR +/-: vehicle, white bars; MCH, hatched bars; MCHIR -/-: vehicle, shaded bars; MCH, striped bars). P values are from comparisons between treatment groups of the same genotype (*) or between genotypes of the same treatment (**). * $P < 0.005$, ** $P < 0.01$.

DETAILED DESCRIPTION OF THE INVENTION

MCHIR deficient mice contain an alteration in one or both MCHIR alleles that substantially reduces expression of a functional MCHIR from the altered allele. The production of MCHIR deficient mice is illustrated by a viable MCHIR -/- knockout mouse where expression of MCHIR is eliminated from both MCHIR alleles. Based on the guidance provided herein concerning the production of such viable MCHIR -/- mice, MCHIR deficient mice containing different types of alterations in one or both MCHIR allele can be produced.

MCHIR deficient mice have a variety of uses such as being used as a tool to examine the physiological roles of MCHIR, to evaluate the ability of compounds to target MCHIR, and to evaluate the ability of compounds to compensate for a deficiency in MCHIR. The ability of compounds to target MCHIR or to compensate for a MCHIR deficiency can be evaluated by measuring changes in one or more phenotypes associated with a MCHIR deficiency.

Studies involving MCHIR mice are preferably performed using mice with an alteration in both MCHIR alleles. Mice containing an alteration in one allele are preferably used as an intermediate animal in the initial production of mice having alterations in both alleles. Propagation of mice with an alteration in both alleles is preferably achieved using male and female mice containing alterations in both MCHIR alleles.

Phenotypes observed in MCHIR deficient mice include reduced fat mass, increased food consumption when mice are maintained on regular chow, hyperactivity, neuroendocrine abnormalities, increased energy expenditure as

measured by indirect calorimetry, reduced respiratory quotient as measured by indirect calorimetry, decreased sensitivity to diet-induced obesity, resistance to the orexigenic effects of intracerebroventricular administration of MCH and resistance to the anorectic effects of intracerebroventricular administration of a peptide antagonist of

5 MCHIR.

The observed phenotypes of MCHIR deficient mice point to additional phenotypes associated with energy metabolism alterations. Such additional phenotypes include one or more of the following: increased muscle mass; altered glucose or insulin tolerance, as for instance measured by an oral glucose tolerance test or an intraperitoneal insulin tolerance test; altered sensitivity to intracerebroventricularly administered peptide and non-peptide agonists and antagonists of MCHIR and of other energy expenditure pathways; and altered responsiveness to modulation of food intake pathways and pathways affecting other aspects of energy expenditure.

10 MCHIR deficient mice with different alterations can have varying degrees of phenotypes associated with a MCHIR $-/-$ knockout mouse. In different embodiments, using techniques described in the Examples below, mice with an MCHIR deficiency consume approximately 12% to approximately 16% more food than MCHIR wild-type mice, and MCHIR deficient mice have approximately a 2-
20 fold increase in dark phase ambulatory activity compared to wild-type mice.

Production of MCHIR Deficient Mice

Based on the guidance provided herein, different types of MCHIR deficient mice can be produced. A preferred scheme for producing MCHIR deficient
25 mice involves producing male and female mice with an altered MCHIR allele and breeding the mice to produce mice having alterations in both alleles.

Techniques for producing mice with an altered genome are well known in the art. (Ausubel, Chapter 23, Manipulating the Mouse Genome, *Current Protocols in Molecular Biology*, John Wiley, 2001). An example of a scheme for
30 producing a mouse with an altered MCHIR allele involves the following:

- (a) altering the MCHIR allele in a mouse embryonic stem cell by homologous recombination with a transgene to produce an altered embryonic stem cell;
- (b) introducing the altered embryonic stem cell into a mouse
35 blastocyst to produce an altered blastocyst;

- (c) introducing the altered blastocyst into a pseudopregnant mouse to produce a pregnant mouse;
- (d) allowing the pregnant mouse to produce offspring; and
- (e) screening the offspring for the presence of an altered MCH1R allele to identify a MCH1R deficient mouse.

Genetic elements involved in gene expression include transcription and translation elements such as a promoter, transcription factor binding sites, splicing sites, polyadenylation region, and ribosome binding site. Removing or altering these elements will decrease or eliminate the production of MCH1R from the MCH1R gene.

MCH1R structural gene alterations can be used to produce an MCH1R derivative having little or no MCH1R activity. A preferred alteration to the MCH1R structural gene involves deleting substantially all of the gene.

A deletion in an MCH1R allele can be accompanied by an insertion of additional nucleic acid. Additional nucleic acid that may be inserted includes nucleic acid encoding a selectable marker having an independent promoter and nucleic acid encoding a reporter protein transcriptionally coupled to the MCH1R promoter. Examples of reporter protein that can be used in chimeric mice are β -galactosidase (*lacZ*) and green fluorescent protein (GFP) and its derivatives.

Initial alterations are preferably produced using a transgene containing one or more selectable markers and nucleic acid targeting MCH1R for insertion by homologous recombination. Homologous recombination can be performed to create alterations in MCH1R and/or remove MCH1R regions. Markers can be used to facilitate screening for the insertion into a mouse genome, for the insertion occurring by homologous recombination (Ausubel, Chapter 23, *Manipulating the Mouse Genome, Current Protocols in Molecular Biology*, John Wiley, 2001), and for evaluating mRNA localization and expression.

A transgene used for homologous recombination may contain recombinase systems, which may be employed to excise inserted nucleic acid. Examples of recombinase systems include the bacteriophage recombinase Cre/*loxP* system and the yeast recombinase Flp/FRT system. (Ausubel, Chapter 23, *Manipulating the Mouse Genome, Current Protocols in Molecular Biology*, John Wiley, 2001, and U.S. Patent No. 5,564,182.) *loxP* recognition sites can be positioned 3' and 5' of a region to be removed and excised by Cre recombinase.

Similarly, *frt* recognition sites can be positioned 3' and 5' of a region to be removed and excised by Flp recombinase.

- Screening for mice containing an altered MCH1R allele can be achieved using techniques such as those measuring the production of MCH1R mRNA transcripts and whether any produced MCH1R transcript is different from wild-type transcript. Techniques for measuring MCH1R mRNA transcripts and the type of transcript include nucleic acid hybridization analysis such as a northern blot analysis which can detect the production and size of transcripts with the use of smaller nucleic acid probes specific for a particular sequence. Polymerase chain reaction (PCR) or *in situ* hybridization can also be employed to measure MCH1R mRNA transcripts.
- Whether or not a particular alteration substantially reduces expression of a functional MCH1R can be determined by producing mice containing such alterations in both alleles. The phenotype of mice containing the alteration in both alleles is determined by comparing the phenotypes of MCH1R *-/-* knockout mice and MCH1R wild-type mice.

Assays Involving MCH1R Mice

- Assays involving MCH1R deficient mice can be performed to measure the effect of a compound on a MCH1R deficiency. Such assays can be performed for different purposes such as evaluating the ability of a compound to compensate for a MCH1R deficiency and evaluating the ability of a compound to selectively act at MCH1R.

- The effect of a compound on MCH1R deficiency *in vivo* can be evaluated by measuring one or more phenotypes associated with MCH1R.
- Techniques for measuring different activities such as food consumption, body weight, stress, anxiety, locomotor activity, sleep, fatigue, circadian rhythm, and energy metabolism are well known in the art. (See, for example, Crawley, J.N., What's Wrong with My Mouse, Wiley-Liss, 2000, Chen, *et al.*, 2000. *Trans. Res.* 9, 145-154 and Chen, *et al.*, 2000. *Nat. Genetics* 26, 97-102.) Examples of techniques for measuring some these different activities are described in the Examples provided below.

In different embodiments, compounds administered to MCH1R deficient mice have previously been identified as MCH1R or MCH2R active compounds using an *in vitro* assay. MCH2R is another receptor that binds MCH.

MCH1R and MCH2R active compounds modulate activity of either or both MCH1R and MCH2R, and include agonists, antagonists, and allosteric modulators.

The ability of a compound to affect *in vitro* MCH1R or MCH2R activity can be determined using a cloned receptor and measuring receptor activity.

- 5 The amino acid and encoding cDNA sequences for human MCH1R and MCH2R are provided by SEQ. ID. NOS. 1-4. SEQ. ID. NOS. 1 and 2 provide the amino acid and encoding cDNA for human MCH1R. SEQ. ID. NOS. 3 and 4 provide the amino acid and encoding cDNA for human MCH2R.

- 10 MCH1R and MCH2R are G protein coupled receptors. MCH1R couples to both Gi and Gq, while MCH2R couples to Gq. Coupling of Gi results in the inhibition of adenylate cyclase and subsequent reductions in cAMP levels. Coupling to Gq leads to activation of phospholipase C and subsequent elevation of intracellular Ca^{2+} .

- 15 Recombinantly expressed receptor can be used to facilitate determining whether a compound is active at that receptor. For example, MCH1R or MCH2R can be expressed by an expression vector in a cell line such as HEK 293, COS 7, and CHO not normally expressing the receptor, where the same cell line without the expression vector or with an expression vector not encoding the receptor can act as a control.

- 20 Techniques for measuring different G-protein activities, such as Gi, Gs, and Gq are well known in the art. Gi and Gs activity can be measured using techniques such as a melonaphore assay, assays measuring cAMP production, assays measuring inhibition of cAMP accumulation, and assays measuring binding of 35S-GTP. cAMP can be measured using different techniques such as a radioimmunoassay
25 and indirectly by cAMP responsive gene reporter proteins.

- Gq activity can be measured using techniques such as those measuring intracellular Ca^{2+} . Examples of techniques well known in the art that can be employed to measure Ca^{2+} include the use of dyes such as Fura-2 and the use of Ca^{2+} -bioluminescent sensitive reporter proteins such as aequorin. An example of a cell line
30 employing aequorin to measure G-protein activity is HEK293/aeq17. (Button, *et al.*, 1993. *Cell Calcium* 14, 663-671, and Feighner, *et al.*, 1999. *Science* 284, 2184-2188.)

Compounds modulating MCH1R activity include agonists, antagonists and allosteric modulators. The ability of a test compound to antagonize MCH1R can

be measured by activating the receptor using an MCH1R agonist and measuring the effect of the test compound on MCH1R activity.

- MCH1R and MCH2R active compounds have therapeutic applications. Such applications include the ability to achieve one or more of the following: weight loss (e.g., treat obesity), weight gain, treat cancer (e.g., colon or breast), reduce pain, treat diabetes, reduce stress and anxiety, treat locomotor deficits, treat sexual dysfunction, treat fatigue, or treat sleep disorders.

Additional Assays

- 10 The increased locomotor activity of MCH1R deficient mice points to associations between MCH1R and stress, anxiety, fatigue, circadian rhythm, and sleep. Compounds affecting stress, anxiety, fatigue, circadian rhythm, or sleep, can be identified using an *in vitro* MCH1R assay followed by an *in vivo* assay. The *in vivo* assay is performed in a mammal such as a mouse, rat, dog, ferret or monkey.
- 15 Compounds affecting locomotor activity, stress, anxiety, fatigue, circadian rhythm, or sleep can be used as a research tool and to achieve useful effects in a patient. Useful effects include reducing stress, anxiety or fatigue, and altering sleep patterns. Alteration of sleep patterns is useful to, for example, treat sleep disorders and treat jet lag. Preferably, the patient is human patient.
- 20 In different embodiments, the ability of a MCH1R active compound that increases MCH1R activity is tested in an *in vivo* assay that measures a decrease in stress, anxiety or locomotor activity; the ability of a MCH1R active compound that decreases MCH1R activity is tested in an *in vivo* assay that measures a reduction in fatigue and the ability of a compound to modulate MCH1R activity is tested in an *in vivo* assay
- 25 that measures alterations in circadian rhythm or sleep.

EXAMPLES

- Examples are provided below to further illustrate different features of the present invention. The examples also illustrate useful methodology for practicing the invention. These examples do not limit the claimed invention.

Example 1: Generation of MCH1R -/- Mice

- MCH1R -/- mice were produced using recombinant techniques to obtain MCH1R +/- mice and breeding the MCH1R +/- mice. Production of MCH1R +/- mice involved using an MCH1R targeting vector to disrupt the MCH1R allele in

embryonic stem (ES) cells, injecting the transformed ES cells into a blastocyst, implanting the blastocyst into a pseudopregnant female, and identifying MCH1R +/- offspring.

5 A 14 Kb mouse genomic clone containing MCH1R was obtained from a mouse 129SvJ lambda genomic library (Lambda FIX II Library, Stratagene, La Jolla, CA). The clone was identified by screening the library with a 500 bp mouse MCH1R cDNA probe generated from MCH1R by PCR using primers derived from the rat MCH1R sequence. The rat MCH1R sequence is described as the rat SLC-1 in Lakaye, *et al.*, 1988. *Biochim. Biophys. ACTA* 1401:216-220.

10 The MCH1R targeting vector was made up of two homologous recombination targeting regions, a positive selection element, and a negative selection element (Figure 1). The two homologous recombination targeting regions were obtained from the mouse genomic clone. One of the regions was a 6.5 Kb 5' MCH1R KpnI to KpnI fragment. The second region was an 1.4 kb 3' MCH1R BamHI to XbaI fragment.

15 PGKneo was used as the positive selection element and HSV-thymidine kinase was used as the negative selection element. PGKneo provides for neomycin resistance, which serves as a positive selection for integration into the mouse genome. HSV-thymidine kinase provides for sensitivity to acyclovir and its analogs, providing for a negative selection against integration not involving homologous recombination.

20 Homologous recombination of the targeting vector into the mouse genome was performed by linearizing the targeting vector with NotI and transforming AB2.2 ES cells by electroporation. Electroporation was performed with 1×10^7 AB2.2 ES cells and 25 μ g of vector under standard conditions using a BioRad Gene Pulser (Instruction manual, Lexicon Genetics, The Woodlands, Texas 77381, Catalog number K100). Transfected cells were then cultured with G418/FIAU for positive and negative selections, respectively. FIAU is the uracil derivative; 2'-fluoro-2'-deoxy-1beta-D-arabinofuranosyl-5-iodo-uracil. Approximately 500 neomycin resistant clones were selected and Southern blot analysis revealed ten correctly targeted ES cell clones in which one of the two MCH1R alleles was successfully replaced by the PGK-neomycin resistance cassette.

30 The ten ES cell clones were expanded and microinjected into mouse blastocysts. Mouse blastocysts were implanted into a pseudopregnant female mice. (Gene Targeting, a practical approach, Joyner A.L. eds, IRL press, 1993.) The

35

implanted mice were allowed to go to term. Transgenic MCH1R +/- offspring were identified by Southern analyses.

Transgenic MCH1R -/- mice were produced by breeding male and female MCH1R +/- mice. MCH1R -/- mice were produced in the expected Mendelian ratio. The absence of MCH1R alleles was verified by Southern blot and PCR genotyping. MCH1R -/- mice of both sexes are fertile and their growth rates are comparable to that of wild-type littermate controls out to approximately 20 weeks of age. MCH1R -/- mice greater than approximately 20 weeks of age exhibit slightly, but significantly, lower body weights as compared to wild-type littermate mice.

PCR genotyping was performed using a Qiagen HotStart PCR kit following the Qiagen protocol. Three different oligonucleotide primers were used to distinguish the knockout allele from the wild-type allele. MCH-5L2 (SEQ. ID. NO. 5): 5'- AAA TTG CTA GGG AGG CTT GCA G - 3'; neo-5 (SEQ. ID. NO. 6): 5'- TAA AGC GCA TGC TCC AGA CTG CCT T - 3'; MCH-3t (SEQ. ID. NO. 7): 5'- TTA AAG GAA CCC AAG CTA GGC ACC - 3'. Primer pair MCH-5L2 and MCH-3t generates a 190 bp fragment from the wild-type MCH1R allele, while primer pair neo-5 and MCH-3t generates a 260 bp fragment from the disrupted MCH1R allele.

Southern blot analysis was performed using a 3' probe and a coding region probe. (Sambrook, *et al.*, Molecular Cloning, a Laboratory Manual, 2nd ed. 1989). The 3' flanking probe is a 0.95 kb PCR fragment located 180 bp 3' of the short arm of the targeting vector. Upon EcoRV-HpaI digestion, the probe detects a 6.0 kb band from the wild-type MCH1R allele, and a 4.2 kb band from the mutant allele (Figure 1).

The coding region probe is a 1.1 kb Kpn-BamHI fragment covering a portion of the MCH1R coding region, including the first transmembrane domain to the stop codon. The coding region probe also detects a 6.0 kb wild-type band on EcoRV-HpaI digested genomic DNA, but detects no signal from the knocked out allele.

Mouse cDNA encoding for MCH1R and the mouse MCH1R sequences are provided by SEQ. ID. NOS. 10 and 11. SEQ. ID. NO. 10 provides the cDNA sequence. SEQ. ID. NO. 11 provides the amino acid sequence.

Example 2: *In Situ* Hybridization

In situ hybridization was performed to verify the absence of MCH1R mRNA in the brain of MCH1R $-/-$ mice. MCH1R $-/-$ and age/sex matched wild-type control mice were killed by decapitation, and brains were quickly removed and frozen in -40°C isopentane, and stored at -80°C until use. Coronal brain sections ($14\ \mu\text{M}$) were cut at -17°C with a cryostat microtome and thaw-mounted onto baked microslides. Following fixation in ice-cold 4% phosphate-buffered paraformaldehyde, the tissue sections were stored in 95% ethanol at 4°C until use.

Hybridization was performed using hybridization probes that consist of an equal molar mixture of two non-overlapping, antisense oligonucleotides against the coding region of MCH1R:

Oligo 407 (SEQ. ID. NO. 8):

5'-CTAATGAACGAGAGAGCCCCACAGGAGGCAGATCACCAGGGTGGCC-3'

Oligo 408 (SEQ. ID. NO. 9):

5'-CCAGCACACAAAGAAGACCAGACAGATGGCAATGGCTGTGCGGGT-3'.

The probes were terminally labeled with $[\alpha\text{-}^{33}\text{P}]\text{dATP}$ and terminal transferase, and hybridization and washing conditions were as described in Guan, *et al.*, 1998. *Mol. Brain Res.* 59, 273-279. mRNA transcripts were observed in wild-type mice, but not in MCH1R $-/-$ mice.

Example 3: Evaluation of Body Composition

Evaluations of body composition were performed using 5-7-month-old male and female MCH1R $+/+$, MCH1R $+/-$, and MCH1R $-/-$ littermate mice. Body composition was analyzed by dual energy x-ray absorptiometry (DEXA; QDR 4500, Hologic, Inc.), using the QDR 4500 Small Animal Studies software version 9.0.

DEXA revealed that both male and female 5-7-month-old MCH1R $-/-$ mice were significantly leaner than wild-types (Figure 2). Both genders of MCH1R $-/-$ mice possessed $\sim 50\%$ less fat mass and $\sim 7\%$ more lean mass than wild-types. Male and female MCH1R $+/-$ mice exhibited normal body composition.

Evaluation of a subset of individual fat pads and DEXA analysis of individually-housed animals from the second line corroborated the lean phenotype.

Example 4: Food Intake Measurement

Food intake measurements were performed using male and female MCH1R $+/+$, MCH1R $+/-$, and MCH1R $-/-$ mice. The mice were separated into individual microisolator cages at approximately one month of age and at least seven

5 days prior to the initiation of any experiment. Regular mouse chow (Teklad 7012; 5% fat, 19% protein, and 5% fiber; 3.41 grams/kcal and 14.8% kcal from fat) was provided to 9.5-10-week-old mice as pellet food in wire cage tops containing food hoppers. Food was weighed daily for 4 days. Food intake reported as the average food consumed per mouse per day over the

10 course of the four-day period is shown in Table 1.

Table 1. Daily Food Consumption of Male and Female MCH1R Mice

| Gender and Genotype | Daily Food Consumption (g/mouse/day) Mean \pm SEM | n value | P value |
|---------------------|-----------------------------------------------------------|------------|------------------------------------------------------|
| Male MCH1R $+/+$ | 4.18 \pm 0.14 | 11 | |
| Male MCH1R $+/-$ | 4.26 \pm 0.12 | 10 | |
| Male MCH1R $-/-$ | 4.84 \pm 0.18* | 11 | *, < 0.02 vs. $+/+$; [#] , <0.02 vs. $+/-$ |
| Female MCH1R $+/+$ | 4.06 \pm 0.16 | 10 | |
| Female MCH1R $+/-$ | 3.70 \pm 0.44* | 4 | |
| Female MCH1R $-/-$ | 4.56 \pm 0.15* | 8 | *, < 0.04 vs. $+/+$; [#] , <0.04 vs. $+/-$ |

15 Both male and female MCH1R $-/-$ mice are significantly hyperphagic. Male and female MCH1R $-/-$ mice consumed approximately 16% and 12% more food, respectively, than wild-type control mice.

Example 5: Assessment of Ambulatory Activity and Fine Movements

20 Ambulatory activity and fine movement studies were performed using MCH1R $+/+$, MCH1R $+/-$ and MCH1R $-/-$ mice. The locomotor activity of male MCH1R $+/+$, MCH1R $+/-$, and MCH1R $-/-$, and female MCH1R $+/+$, MCH1R $+/-$ and MCH1R $-/-$ 8-9-week-old littermate mice was examined using a cage rack Photobeam Activity System (San Diego Instruments). Mice were housed individually in

25 transparent plexiglass cages (40 x 20 x 20 cm) for several weeks prior to evaluation. The results of the ambulatory activity and fine movement studies are shown in Tables 2 and 3. During examination two consecutive photobeam breaks occurring in adjacent photobeams was scored as ambulatory movement. Two or more

- consecutive photobeam breaks occurring in the same photobeam, with no other photobeams being interrupted, was scored as fine movements. The total number of ambulatory movements in a given part of the light cycle multiplied by the distance between two adjacent photobeams (0.053975 m) equaled the total distance traveled during that given part of the light cycle. MCH1R $-/-$ mice of both sexes exhibit approximately a 2-fold increase in dark phase ambulatory activity.

Table 2. Ambulatory Activity of Male and Female MCH1R Mice

| Gender and Genotype | Ambulatory Activity (meters traveled) Mean \pm SEM | | N value | P value | |
|---------------------|------------------------------------------------------------|------------------------------------|------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
| | Light phase | Dark phase | | Light phase | Dark phase |
| Male MCH1R+/+ | 31.20 \pm 6.49 | 114.35 \pm 16.38 | 11 | | |
| Male MCH1R+/- | 19.19 \pm 4.61 | 98.73 \pm 7.26 | 6 | | |
| Male MCH1R-/- | 49.74 \pm 6.09 ^a | 223.70 \pm 29.32 ^a | 11 | ^a , = 0.05 vs. +/+; ^a , <0.004 vs. +/- | ^a , <0.005 vs. +/+; ^a , <0.008 vs. +/- |
| Female MCH1R+/+ | 29.39 \pm 6.37 | 105.52 \pm 11.93 | 10 | | |
| Female MCH1R +/- | 64.03 \pm 21.14 | 100.23 \pm \pm 17.30 | 4 | | |
| Female MCH1R-/- | 57.55 \pm 13.41 ^a | 209.81 \pm 19.64 ^a | 8 | ^a , = 0.06 vs. +/+ | ^a , <0.001 vs. +/+; ^a , <0.006 vs. +/- |

10

Table 3. Fine Movements of Male and Female MCH1R Mice

| Gender and Genotype | Fine Movements (number of beam breaks) Mean \pm SEM | | N value | P value | |
|---------------------|-------------------------------------------------------------|--------------------------------------|------------|-------------|---------------------------------------------------------------|
| | Light phase | Dark phase | | Light phase | Dark phase |
| Male MCH1R+/+ | 707.18 \pm 124.07 | 1619.84 \pm 243.26 | 11 | | |
| Male MCH1R+/- | 865.50 \pm 58.70 | 1703.33 \pm 108.86 | 6 | | |
| Male MCH1R-/- | 889.36 \pm 122.11 | 2672.54 \pm 270.36 ^a | 11 | | ^a , <0.01 vs. +/+; ^a , <0.03 vs. +/- |
| Female MCH1R+/+ | 1034.4 \pm 121.27 | 1969.25 \pm 89.01 | 10 | | |
| Female MCH1R +/- | 1209.25 \pm 234.84 | 2098.75 \pm 472.62 | 4 | | |
| Female MCH1R-/- | 1178.75 \pm 163.29 | 2429.00 \pm 88.16 ^a | 8 | | ^a , <0.005 vs. +/- |

Example 6: Assessment of Metabolic Rate and Respiratory Quotient

Metabolic rate and respiratory quotient were evaluated by indirect calorimetry using MCH1R $+/+$ and MCH $-/-$ mice. The locomotor activity of male MCH1R $+/+$ and MCH1R $-/-$ 12-week-old littermate mice was examined using a 16-chamber open-circuit Oxymax system (Columbus Instruments). Mice were housed individually in transparent plexiglass cages (40 x 20 x 20 cm) for several weeks prior to evaluation.

MCH1R $-/-$ mice exhibited a significantly greater metabolic rate during a portion of the dark phase of the light-dark cycle (Figure 3) that was temporally correlated with the period of hyperactivity, suggesting that this increase in metabolic rate is secondary to the hyperactivity. The respiratory quotient, an indicator of metabolic fuel preference, was significantly lower in male MCH1R $-/-$ mice during the light phase, but was indistinguishable from that of wild-types during the dark phase (Figure 4), implying that MCH1R $-/-$ mice rely upon the oxidation of free fatty acids and less upon glycolysis during periods when they are not actively eating.

Example 7: Assessment of Neuroendocrine Profile

Neuroendocrine profiles were evaluated in male and female MCH1R $+/+$ and MCH $-/-$ littermate mice. Plasma leptin, insulin, total T4 and corticosterone levels were measured by RIA. Plasma glucose and triglyceride levels were measured by enzyme-colorimetric assays (Sigma and Roche, respectively).

Plasma glucose, insulin and triglyceride levels were not significantly different in 5-7-month-old MCH1R $-/-$ and wild-type littermates of either gender (Table 4). Plasma leptin and total thyroxine (T4) levels were significantly lower in male *Mchl^r^{-/-}* mice relative to wild-types, and female levels revealed similar trends (Table 4). Lower leptin levels are consistent with the lean phenotype and lower T4 levels support the notion that MCH may be involved in the regulation of thyroid function (Kennedy, *et al.*, 2000. *Endocrinology* 142:3265-3268). Alternatively, alterations in T4 levels may reflect a compensatory response to the increased energy expenditure. Plasma corticosterone levels were significantly greater in 6-7-month-old male *Mchl^r^{-/-}* mice relative to wild-type littermates (Table 4). This is consistent with the finding that MCH administration reduces basal and stress-induced plasma ACTH levels in rats (Bluet-Pajot, *et al.*, 1995. *J. Neuroendocrinol.* 7:297-303), and suggests that MCH1R may be involved in the regulation of adrenal function.

Table 4. Neuroendocrine Profiles of Male and Female MCH1R Mice.

| | Males | | Females | |
|------------------------|-------------|--------------|-------------|-------------|
| | MCH1R +/+ | MCH1R -/- | MCH1R +/+ | MCH1R -/- |
| Leptin (ng/ml) | 6.05 ± 1.99 | 2.12 ± 0.08* | 3.87 ± 0.92 | 2.31 ± 0.06 |
| Triglyceride (mg/dl) | 77 ± 10 | 69 ± 6 | 57 ± 7 | 64 ± 5 |
| Insulin (ng/ml) | 0.61 ± 0.15 | 0.57 ± 0.12 | 0.31 ± 0.04 | 0.33 ± 0.04 |
| Glucose (mg/dl) | 140 ± 7 | 137 ± 5 | 132 ± 5 | 123 ± 4 |
| T4 (µg/dl) | 5.35 ± 0.25 | 4.32 ± 0.23* | 4.58 ± 0.37 | 4.05 ± 0.22 |
| Corticosterone (ng/ml) | 9 ± 1.1 | 23.6 ± 5.4* | ND | ND |

- Plasma leptin, triglyceride, insulin, glucose and total thyroxine (T4) levels of group-housed male and female 5-7-month-old MCH1R littermate mice (n = 10-14 per group). Plasma corticosterone levels of individually-housed 6-7-month-old male MCH1R littermate mice (n = 9-10 per genotype) maintained in isolation and fed *ad libitum*. *P ≤ 0.05; ND, not determined.

Example 8: Assessment of Neuropeptide Expression.

- 10 Corticotrophin-releasing factor (CRF) mRNA levels in the brain were measured by *in situ* hybridization. CRF mRNA levels in the paraventricular nucleus of the hypothalamus (PVN) were significantly lower in male MCH1R -/- mice relative to wild-types, yet were normal in the central nucleus of the amygdala (CEA) (PVN: MCH1R -/-, 79.5 ± 9.6 Ci/g tissue; MCH1R +/+, 105.3 ± 10.1 Ci/g tissue; P < 0.05;
- 15 CEA: MCH1R -/-, 57.5 ± 1.3 Ci/g tissue; MCH1R +/+, 57.0 ± 5.9 Ci/g tissue; n = 5 per genotype). This suggests that the elevated corticosterone levels are not due to increased hypothalamic CRF. Instead, it is likely that the reduced CRF expression in the PVN is a consequence of negative feedback driven by the elevated levels of corticosterone. In contrast to CRF, hypothalamic levels of neuropeptide Y (NPY),
- 20 agouti-related protein (AgRP), galanin, pro-opiomelanocortin, and cocaine- and amphetamine-regulated transcript mRNAs measured during the light phase were all normal in MCH1R -/- mice.

Example 9: Assessment of Responsiveness to Diet-induced Obesity.

Female wild-type mice maintained on a high fat diet for seven weeks gained significantly more body weight than wild-type littermates maintained on regular chow (Figure 5). In contrast, female MCH1R $-/-$ mice maintained on the high fat diet gained the same amount of body weight as MCH1R $-/-$ littermates maintained on regular chow. This decreased susceptibility to diet-induced obesity is most likely a consequence of the hyperactivity and associated increase in energy expenditure. Interestingly, maintenance on the high fat diet abolished the significant hyperphagia (24.3 %) observed with maintenance on regular chow (Figure 6).

Example 10: Assessment of Responsiveness to Centrally Administered Orexigenics.

MCH1R $-/-$ mice exhibited normal responses to both acute left lateral and dorsal third ventricle administrations of NPY and AgRP, demonstrating that MCH1R is not required for their orexigenic actions. Additionally, these data suggest that the hyperphagia is not a consequence of heightened NPY or AgRP signaling. Acute administrations of MCH were without significant effects, but tended to increase the food intake of only wild-types. Subsequently, the responses of MCH1R $-/-$ and wild-type littermates to chronic dorsal third ventricle infusions of MCH were evaluated. Six days of chronic MCH treatment resulted in significantly greater food intake (Figure 7), body weight gains (Figure 8) and altered body composition (Figure 9) in wild-types, while MCH1R $-/-$ littermates were not affected, demonstrating that MCH1R is required for the orexigenic actions of MCH.

Other embodiments are within the following claims. While several embodiments have been shown and described, various modifications may be made without departing from the spirit and scope of the present invention.

WHAT IS CLAIMED IS:

1. A melanin concentrating hormone type 1 receptor (MCH1R) deficient mouse whose genome comprises an alteration in one or both MCH1R alleles, wherein said alteration substantially reduces expression of a functional MCH1R.
2. The mouse of claim 1, wherein said mouse comprises said alteration in one allele and said alteration comprises a transgene insertion eliminating expression of functional MCH1R.
3. The mouse of claim 1, wherein said mouse comprises said alteration in both alleles, and said alteration comprises a transgene insertion eliminating expression of functional MCH1R.
4. The mouse of claim 1, wherein said mouse comprises said alteration in one allele and said alteration comprises the complete removal of MCH1R encoding nucleic acid.
5. The mouse of claim 1, wherein said mouse comprises said alteration in both alleles and said alteration comprises the complete removal of MCH1R encoding nucleic acid.
6. A method of producing a MCH1R deficient mouse comprising an alteration of the MCH1R gene in an MCH1R allele comprising the steps of:
 - (a) altering said MCH1R allele in a mouse embryonic stem cell by homologous recombination with a transgene to produce an altered embryonic stem cell;
 - (b) introducing said altered embryonic stem cell into a mouse blastocyst to produce an altered blastocyst;
 - (c) introducing said altered blastocyst into a pseudopregnant mouse to produce a pregnant mouse;
 - (d) allowing said pregnant mouse to produce offspring; and
 - (e) screening said offspring for the presence of an altered MCH1R allele to identify said MCH1R deficient mouse.

7. The method of claim 6, wherein said altering eliminates expression of functional MCH1R.
- 5 8. A method of producing a MCH1R deficient mouse comprising an altered MCH1R in both alleles comprising the steps of:
- (a) breeding two mice each comprising an alteration of the MCH1R in one allele to produce offspring; and
- (b) screening said offspring for the presence of said altered
- 10 MCH1R in both alleles to identify said MCH1R deficient mouse.
9. The method claim 8, wherein said alteration comprises a transgene insertion eliminating expression of functional MCH1R.
- 15 10. The mouse of claim 8, wherein alteration comprises the complete removal of MCH1R encoding nucleic acid.
11. A method of measuring the affect of a compound on a MCH1R deficiency comprising the steps of providing said compound to the MCH1R mouse of
- 20 any one of claims 1-5, and measuring one or more phenotypes associated with MCH1R activity.
12. The method of claim 11, wherein said phenotype is hyperphagic or hypophagic activity.
- 25 13. The method of claim 11, wherein said phenotype is a change in fat mass.
14. The method of claim 11, wherein said phenotype is a change in
- 30 muscle mass.
15. The method of claim 11, wherein said phenotype is increased or decreased locomotor activity.

16. The method of claim 11, wherein said phenotype is increased or decreased fine motor movements.

17. The method of claim 11, wherein said phenotype is an
5 increased or decreased metabolic indicator selected from the group consisting of: oxygen consumption, carbon dioxide production, metabolic rate, pseudo-resting metabolic rate, respiratory exchange ratio and respiratory quotient.

18. The method of claim 11, wherein said compound is active at
10 MCH2R.

19. A method of screening for a compound affecting stress, anxiety, fatigue, locomotor activity, circadian rhythm, or sleep comprising the steps of:

- 15 (a) identifying an MCH1R active compound able to modulate MCH1R activity using an *in vitro* assay; and
(b) measuring the ability of said MCH1R active compound on stress, anxiety, fatigue, locomotor activity, circadian rhythm, or sleep using an *in vivo* assay.

20 20. The method of claim 19, wherein said method is performed to screen for a compound to affect stress or anxiety, said MCH1R active compound identified in said step (a) causes an increase in MCH1R activity and said *in vivo* assay employed in said step (b) measures the ability of said MCH1R active compound to
25 decrease stress or anxiety.

21. The method of claim 20, wherein said method is performed to screen for a compound to affect fatigue, said MCH1R active compound identified in said step (a) causes a decrease in MCH1R activity and said *in vivo* assay employed in
30 said step (b) measures the ability of said MCH1R active compound to affect fatigue.

22. The method of claim 20, wherein said method is performed to screen for a compound to affect circadian rhythm and said *in vivo* assay employed in said step (b) measures the ability of said MCH1R active compound to affect circadian
35 rhythm.

23. The method of claim 20, wherein said method is performed to screen for a compound to affect sleep and said *in vivo* assay employed in said step (b) measures the ability of said MCH1R active compound to affect sleep.

5

24. The method of claim 20, wherein said method is performed to screen for a compound to affect locomotor activity and said *in vivo* assay employed in said step (b) measures the ability of said MCH1R active compound to affect locomotor activity.




Fig. 1




Fig. 2A




Fig. 2B




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9

SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> MCH-1R DEFICIENT MICE

<130> 20829Y PCT

<150> 60/278,061

<151> 2001-03-22

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 353

<212> PRT

<213> Human

<400> 1

```

Met Asp Leu Glu Ala Ser Leu Leu Pro Thr Gly Pro Asn Ala Ser Asn
 1          5          10
Thr Ser Asp Gly Pro Asp Asn Leu Thr Ser Ala Gly Ser Pro Pro Arg
 20        25        30
Thr Gly Ser Ile Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe Gly
 35        40        45
Thr Ile Cys Leu Leu Gly Ile Ile Gly Asn Ser Thr Val Ile Phe Ala
 50        55        60
Val Val Lys Lys Ser Lys Leu His Trp Cys Asn Asn Val Pro Asp Ile
 65        70        75        80
Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Gly Gly Met
 85        90        95
Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe Gly
100        105        110
Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe
115        120        125
Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile Asp Arg Tyr Leu Ala
130        135        140
Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Val Ala
145        150        155        160
Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr
165        170        175
Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala Val
180        185        190
Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp Phe
195        200        205
Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val Ile
210        215        220
Thr Ala Ala Tyr Val Arg Ile Leu Gln Arg Met Thr Ser Ser Val Ala
225        230        235
Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr Lys Arg Val Thr Arg
245        250        255
Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val Cys Trp Ala Pro Tyr
260        265        270
Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser Arg Pro Thr Leu Thr
275        280        285
Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu Gly Tyr Ala Asn Ser
290        295        300
Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys Glu Thr Phe Arg Lys
305        310        315        320

```

Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln Gly Gln Leu Arg Ala
 325 330 335
 Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg Thr Glu Ser Lys Gly
 340 345 350
 Thr

<210> 2
 <211> 1062
 <212> DNA
 <213> Human

<400> 2
 atggacctgg aagcctcgct gctgccact ggtcccaacg ccagcaacac ctctgatggc 60
 ccgataaac tcacttcggc aggatcacct cctcgcaagg ggagcatctc ctacatcaac 120
 atcatcatgc ctccggtgtt cggcacatc tcctcctcgg gcatcctcgg gaactccacg 180
 gtcatctctg cggctcgtgaa gaagtcacag ctgcacttgg gcacaaaggt ccccgacatc 240
 ttcatcatca accctctcgg agtagatctc ctcttctccc tgggcatgcc ctctcatgatc 300
 caccagctca tgggcaatgg ggtgtggcac gctcaccag accatcatcc tgacgcccat ggccattgac 360
 gccatggatg ccaatgtcca gtccaccag ccccatctct tccacgaagt tccggaagcc ctctgtggcc 420
 cgtcactcgg ccaactgtcca cccatctctc gtgggcccct tccttcatca gcatcaccac tctgtggctg 480
 accctgggga tctgctctct gtgggcccct tccttcatca gcatcaccac tctgtggctg 540
 tatgcacagc tcactccctt cccaggaggt gcagtgggct gcggcatacg cctgcacca 600
 ccagacactg accctactct gtccaccctg taccagtttt tctgtggcctt tgcctgcct 660
 tttgtggatc tccacagcgc atactgtgag atctcgagc gcattgacgtc ctccagtggc 720
 cccgcctccc agcgcagcat ccgctcgagg acaagagagg tgaccgccac agccatcgcc 780
 atctgtcttg tcttctttgt gtgctgggca cctactatg tgctacagct gaccagttg 840
 tccatcagcc gcccgacct cacttttgt tactatata atgcggccat cagcttggggc 900
 tatgccaaac gctgcctcaa cccctttgtg tacatcgtgc tctgtgagac gttccgcaaa 960
 cgcttggtcc tgcggtgaa gctcgagcc cagggggcag ttcgcctgt cagcaacgct 1020
 cagacggctg acgaggagag gacagaagcg aaggccacct ga 1062

<210> 3
 <211> 340
 <212> PRT
 <213> Human

<400> 3
 Met Asn Pro Phe His Ala Ser Cys Trp Asn Thr Ser Ala Glu Leu Leu
 1 5 10 15
 Asn Lys Ser Trp Asn Lys Glu Phe Ala Tyr Gln Thr Ala Ser Val Val
 20 25 30
 Asp Thr Val Ile Leu Pro Ser Met Ile Gly Ile Ile Cys Ser Thr Gly
 35 40 45
 Leu Val Gly Asn Ile Leu Ile Val Phe Thr Ile Ile Arg Ser Arg Lys
 50 55 60
 Lys Thr Val Pro Asp Ile Tyr Ile Cys Asn Leu Ala Val Ala Asp Leu
 65 70 75 80
 Val His Ile Val Gly Met Pro Phe Leu Ile His Gln Trp Ala Arg Gly
 85 90 95
 Gly Glu Trp Val Phe Gly Gly Pro Leu Cys Thr Ile Ile Thr Ser Leu
 100 105 110
 Asp Thr Cys Asn Gln Phe Ala Cys Ser Ala Ile Met Thr Val Met Ser
 115 120 125
 Val Asp Arg Tyr Phe Ala Leu Val Gln Pro Phe Arg Leu Thr Arg Trp
 130 135 140
 Arg Thr Arg Tyr Lys Thr Ile Arg Ile Asn Leu Gly Leu Thr Ala Ala
 145 150 155 160
 Ser Phe Ile Leu Ala Leu Pro Val Trp Val Tyr Ser Lys Val Ile Lys
 165 170 175
 Phe Lys Asp Gly Val Glu Ser Cys Ala Phe Asp Leu Thr Ser Pro Asp
 180 185 190

Asp Val Leu Trp Tyr Thr Leu Tyr Leu Thr Ile Thr Thr Phe Phe Phe
 195 200 205
 Pro Leu Pro Leu Ile Leu Val Cys Tyr Ile Leu Ile Leu Cys Tyr Thr
 210 215 220
 Trp Glu Met Tyr Gln Gln Asn Lys Asp Ala Arg Cys Cys Asn Pro Ser
 225 230 235 240
 Val Pro Lys Gln Arg Val Met Lys Leu Thr Lys Met Val Leu Val Leu
 245 250 255
 Val Val Val Phe Ile Leu Ser Ala Ala Pro Tyr His Val Ile Gln Leu
 260 265 270
 Val Asn Leu Gln Met Glu Gln Pro Thr Leu Ala Phe Tyr Val Gly Tyr
 275 280 285
 Tyr Leu Ser Ile Cys Leu Ser Tyr Ala Ser Ser Ser Ile Asn Pro Phe
 290 295 300
 Leu Tyr Ile Leu Leu Ser Gly Asn Phe Gln Lys Arg Leu Pro Gln Ile
 305 310 315 320
 Gln Arg Arg Ala Thr Glu Lys Glu Ile Asn Asn Met Gly Asn Thr Leu
 325 330 335
 Lys Ser His Phe
 340

<210> 4
 <211> 1023
 <212> DNA
 <213> Human

<400> 4
 atgaatccat ttcacgcatc ttgttgaac acctctgcg aacttttaaa caaatcctgg 60
 aataaagagt ttgcttatca aactgccagt gtggtagata cagtcacatcct cctctccatg 120
 attgggatta tctgttcaac agggctgggt ggcaacatcc tcatgtatt cactataata 180
 agatccaggga aaaaaacagt ccttgacatc tatatctgca acctggctgt ggctgatttg 240
 gtccacatag ttggaatgcc tttttattt caccaatggg ccggaggggg agagtgggtg 300
 ttgggggggc ctctctgcac catcatcaca tcccttgata cttgtaacca atttgctgt 360
 agtgcacata tgactgtaat gaggctggac atccggatca atttgggcct accatttcga 420
 ctgacacggt ggagaacaag gtacaagacc tactcgaagg tactcgaatt tggggcagct 480
 tctttatcc ttgcattgcc tbtctgggtc ccttgacatg ccttgacatg tacttgata tacattttat 540
 gtgagagatt gtgcttttga ttgacatcc ccttgattt tgggtgctga tatcttatt 600
 ttgaagataa caactttttt ttcccttcta ccttgattt tgggtgctga tatcttatt 660
 ttatgctata cttgggagat gtatacaac aataaggatg ccagatgctg caatccagct 720
 gtaccaaaac agagagtgat gaagtgcaca aagatgggtc tgggtgctgt ggtagtcttt 780
 attcctgagt ctgcccccta tcatgtgata caactgtgta acttacagat ggaacagccc 840
 acactggcct tctatgtggg ttattacctc tcatctgtc tcagctatgc cagcagcagc 900
 attaacctt tctctacat cctgctgagt ggaatttcc agaaacgtct gcctcaaatc 960
 caaagaagag cgactgagaa ggaaatcaac aatatgggaa acactctgaa atcacacttt 1020
 tag 1023

<210> 5
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer

<400> 5
 aaattgctag ggagggctgc ag

22

<210> 6
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Oligonucleotide primer

<400> 6
taaagcgcat gctccagact gcctt 25

<210> 7
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 7
ttaaaggaac ccaagctagg cacc 24

<210> 8
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide probe

<400> 8
ctaataaacg agagagccca caggaggcag atcaccaggg tggcc 45

<210> 9
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide probe

<400> 9
ccagcacaca aagaagacca gacagatggc aatggctgtg cgggt 45

<210> 10
<211> 1999
<212> DNA
<213> Artificial Sequence

<220>
<223> Mouse cDNA encoding MCH1R

<221> CDS
<222> (138)...(1199)

<400> 10
ggcggtagag gaagaccett ttctggactg cgggggtcaa gctccggaca aggcgggtgga 60
ggcgctggga ggctgcccga gctgcgtgg gtggacgggc gctccactcc agggagcagg 120
cgacctgcac cggctgc atg gat ctg caa gcc tcg ttg ctg tcc act ggc 170
Met Asp Leu Gln Ala Ser Leu Leu Ser Thr Gly
1 5 10

ccc aat gcc agc aac atc tcc gat ggc cag gat aat ttc aca ttg gcg 218
Pro Asn Ala Ser Asn Ile Ser Asp Gly Gln Asp Asn Phe Thr Leu Ala
15 20 25

ggg cca cct cct cgc aca agg agt gtc tcc tac atc aac atc atc atg 266
Gly Pro Pro Pro Arg Thr Arg Ser Val Ser Tyr Ile Asn Ile Ile Met
30 35 40

| | |
|------------------------------------------------------------------------------------------------------------------------------------|------|
| cct tca gtg ttt ggt acc atc tgt ctc ctg ggc att gtg gga aac tcc Pro Ser Val Phe Gly Thr Ile Cys Leu Leu Gly Ile Val Gly Asn Ser | 314 |
| 45 50 55 | |
| aca gtc att ttt gcc gtg gtg aag aaa tcc aag ctg cac tgg tgc agc Thr Val Ile Phe Ala Val Val Lys Lys Ser Lys Leu His Trp Cys Ser | 362 |
| 60 65 70 75 | |
| aac gtc cct gac atc ttc atc atc aac ctc tct gtg gtg gat ctg ctt Asn Val Pro Asp Ile Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu | 410 |
| 80 85 90 | |
| ttc ctg ctg ggc atg cct ttc atg atc cac cag ctg atg ggt aat ggt Phe Leu Leu Gly Met Pro Phe Met Ile His Gln Leu Met Gly Asn Gly | 458 |
| 95 100 105 | |
| gtc tgg cac ttt ggg gaa acc atg tgc acc ctg atc aca gcc atg gac Val Trp His Phe Gly Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp | 506 |
| 110 115 120 | |
| gcc aac agt cag ttc acc agc acc tac atc ctg act gct atg gcc att Ala Asn Ser Gln Phe Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile | 554 |
| 125 130 135 | |
| gac cgc tac ttg gcc acc gtc cat ccc atc tcc tcc acc aag ttc cgg Asp Arg Tyr Leu Ala Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg | 602 |
| 140 145 150 155 | |
| aag ccc tcc atg gcc acc ctg gtg atc tgc ctc ctg tgg gct ctc tgc Lys Pro Ser Met Ala Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser | 650 |
| 160 165 170 | |
| ttc att agc atc act cct gtg tgg ctc tat gcc agg ctt atc ccc ttc Phe Ile Ser Ile Thr Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe | 698 |
| 175 180 185 | |
| cca ggg ggt gct gtg ggc tgt gcc atc cgc cta cca aac cca gat act Pro Gly Gly Ala Val Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr | 746 |
| 190 195 200 | |
| gat ctt tac tgg ttc act ctg tat cag ttt ttc ctg gcc ttc gcc ctt Asp Leu Tyr Trp Phe Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu | 794 |
| 205 210 215 | |
| cag ttt gtg gtc atc act gct gcg tac gtg aaa ata cta cag cgc atg Pro Phe Val Val Ile Thr Ala Ala Tyr Val Lys Ile Leu Gln Arg Met | 842 |
| 220 225 230 235 | |
| acg tct tcg gtg gcc cca gcc tct caa cgc agc atc cgg ctt cgg aca Thr Ser Ser Val Ala Pro Ala Ser Gln Arg Ser Ile Arg Leu Arg Thr | 890 |
| 240 245 250 | |
| aag agg gtg acc cgc aca gcc att gcc atc tgt ctg gtc ttc ttt gtg Lys Arg Val Thr Arg Thr Ala Ile Ala Ile Cys Leu Val Phe Phe Val | 938 |
| 255 260 265 | |
| tgc tgg gcg ccc tac tac gtg ctg cag ctg acc cag ttg tcc atc agc Cys Trp Ala Pro Tyr Tyr Val Leu Gln Leu Thr Gln Leu Ser Ile Ser | 986 |
| 270 275 280 | |
| cgc cgg acc ctc aca ttc gtc tac ctg tac aat gcg gcc atc agc ttg Arg Pro Thr Leu Thr Phe Val Tyr Leu Tyr Asn Ala Ala Ile Ser Leu | 1034 |
| 285 290 295 | |

ggc tat gcc aac agc tgc ctc aat ccc ttt gtg tac ata gta ctc tgt 1082
 Gly Tyr Ala Asn Ser Cys Leu Asn Pro Phe Val Tyr Ile Val Leu Cys 315
 300 305

gag acc ttt cga aaa cgc ttg gtg ctg tgg gtg aag ccc gcg gcc cag 1130
 Glu Thr Phe Arg Lys Arg Leu Val Leu Ser Val Lys Pro Ala Ala Gln 330
 320 325

ggg cag ctt cgc acg gtc agc aat gct cag aca gct gac gag gag agg 1178
 Gly Gln Leu Arg Thr Val Ser Asn Ala Gln Thr Ala Asp Glu Glu Arg 345
 335 340

aca gaa agc aaa ggc acc tga caatcccccc cggtcacctc caagtcagg 1229
 Thr Glu Ser Lys Gly Thr * 350

caccgcatca aaccatgggg agagatactg agataaaaccc ggggctaccc tggggaggatg 1289
 cagaagctgg aggcctggggg cttgtagcaa accacattcc acggggccca caaattgcta 1349
 agaggcttg cagcctggtt tgggggggaa gcctcagact gcagggatccc ccttgactaga 1409
 atagaagcgg agcaagaagg aaagggtggg ttgactgggt ctgggggtct gtactctgtg 1469
 gctcgcatat atcttctctc caaggaagca agcggaaggt gctcacttga 1529
 aactagggcg ggcctagatc tggagcagta gggctctact gtgagactgg gcaagccgag 1589
 cgttccctcc catctctcat tgggtttgat agaaggcagt ctttctccca agctggttga 1649
 tctctcgaag cagcctgctt gggctccagc atctctgtcg gatttcacgt tctcttttag 1709
 ggaatcatgt tgacactggg gtgtgggctc tgagcccaaca ggaatttaaa aaaccaaag 1769
 agctcagagt gtgcagagag acccaatcac cgagaatgac aaggcaacct ggggtggatg 1829
 tggatcttga aactaataaa aagggttttt cacagtgaac gcgacattct cttcatagg 1889
 cacagctgtc agtctatgac tgatccagag cgagcatcca tgaattctgc atgtgcagg 1949
 gtcactctaa tacctgatat gttggcatca tctttgtgct tgagccttcc 1999

<210> 11
 <211> 353
 <212> PRT
 <213> Mouse

<400> 11
 Met Asp Leu Gln Ala Ser Leu Leu Ser Thr Gly Pro Asn Ala Ser Asn
 1 5 10 15
 Ile Ser Asp Gly Gln Asp Asn Phe Thr Leu Ala Gly Pro Pro Arg
 20 25 30
 Thr Arg Ser Val Ser Tyr Ile Asn Ile Ile Met Pro Ser Val Phe Gly
 35 40 45
 Thr Ile Cys Leu Leu Gly Ile Val Gly Asn Ser Thr Val Ile Phe Ala
 50 55 60
 Val Val Lys Lys Ser Lys Leu His Trp Cys Ser Asn Val Pro Asp Ile
 65 70 75 80
 Phe Ile Ile Asn Leu Ser Val Val Asp Leu Leu Phe Leu Leu Gly Met
 85 90 95
 Pro Phe Met Ile His Gln Leu Met Gly Asn Gly Val Trp His Phe Gly
 100 105 110
 Glu Thr Met Cys Thr Leu Ile Thr Ala Met Asp Ala Asn Ser Gln Phe
 115 120 125
 Thr Ser Thr Tyr Ile Leu Thr Ala Met Ala Ile Asp Arg Tyr Leu Ala
 130 135 140
 Thr Val His Pro Ile Ser Ser Thr Lys Phe Arg Lys Pro Ser Met Ala
 145 150 155 160
 Thr Leu Val Ile Cys Leu Leu Trp Ala Leu Ser Phe Ile Ser Ile Thr
 165 170 175
 Pro Val Trp Leu Tyr Ala Arg Leu Ile Pro Phe Pro Gly Gly Ala Val
 180 185 190
 Gly Cys Gly Ile Arg Leu Pro Asn Pro Asp Thr Asp Leu Tyr Trp Phe
 195 200 205
 Thr Leu Tyr Gln Phe Phe Leu Ala Phe Ala Leu Pro Phe Val Val Ile
 210 215 220

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ala | Ala | Tyr | Val | Lys | Ile | Leu | Gln | Arg | Met | Thr | Ser | Ser | Val | Ala |
| 225 | | | | | 230 | | | | | 235 | | | | | 240 |
| Pro | Ala | Ser | Gln | Arg | Ser | Ile | Arg | Leu | Arg | Thr | Lys | Arg | Val | Thr | Arg |
| | | | | | 245 | | | | | 250 | | | | | 255 |
| Thr | Ala | Ile | Ala | Ile | Cys | Leu | Val | Phe | Phe | Val | Cys | Trp | Ala | Pro | Tyr |
| | | | | | 260 | | | | | 265 | | | | | 270 |
| Tyr | Val | Leu | Gln | Leu | Thr | Gln | Leu | Ser | Ile | Ser | Arg | Pro | Thr | Leu | Thr |
| | | | | | 275 | | | | | | | | | | 285 |
| Phe | Val | Tyr | Leu | Tyr | Asn | Ala | Ala | Ile | Ser | Leu | Gly | Tyr | Ala | Asn | Ser |
| | | | | | 290 | | | | | | | | | | 300 |
| Cys | Leu | Asn | Pro | Phe | Val | Tyr | Ile | Val | Leu | Cys | Glu | Thr | Phe | Arg | Lys |
| 305 | | | | | 310 | | | | | 315 | | | | | 320 |
| Arg | Leu | Val | Leu | Ser | Val | Lys | Pro | Ala | Ala | Gln | Gly | Gln | Leu | Arg | Thr |
| | | | | | 325 | | | | | 330 | | | | | 335 |
| Val | Ser | Asn | Ala | Gln | Thr | Ala | Asp | Glu | Glu | Arg | Thr | Glu | Ser | Lys | Gly |
| | | | | | 340 | | | | | 345 | | | | | 350 |
| Thr | | | | | | | | | | | | | | | |

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
3 October 2002 (03.10.2002)

PCT

(10) International Publication Number
WO 02/077168 A3

(51) International Patent Classification: C12P 21/00

MARSH, Donald, J. [US/US]; 126 East Lincoln Avenue,
Rahway, NJ 07065-0907 (US).

(21) International Application Number: PCT/US02/08413

(74) Common Representative: MERCK & CO., INC.; 126
East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(22) International Filing Date: 19 March 2002 (19.03.2002)

(25) Filing Language: English

(81) Designated States (national): CA, JP, US.

(26) Publication Language: English

(84) Designated States (regional): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).

(30) Priority Data:
60/278,061 22 March 2001 (22.03.2001) US

Published:
— with international search report

(71) Applicant (for all designated States except US): MERCK
& CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway,
NJ 07065-0907 (US).

(88) Date of publication of the international search report:
27 March 2003

(72) Inventors; and

(75) Inventors/Applicants (for US only): QIAN, Su [US/US];
126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: MCH1R DEFICIENT MICE

(57) Abstract: The present invention features viable MCH1R deficient mice. MCH1R deficient mice contain an alteration in one or both MCH1R alleles that substantially reduces expression of a functional MCH1R from the altered allele. Preferably, MCH1R deficient mice are MCH1R -/- knockout mice.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/08413

| A. CLASSIFICATION OF SUBJECT MATTER | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IPC(7) : C12F 21/00 US CL. : 800/4 According to International Patent Classification (IPC) or to both national classification and IPC | | | | |
| B. FIELDS SEARCHED | | | | |
| Minimum documentation searched (classification system followed by classification symbols) U.S. : 800/4 | | | | |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched US provisional 60/278,061 | | | | |
| Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST, STN(medline, biosis, embase, caplus) | | | | |
| C. DOCUMENTS CONSIDERED TO BE RELEVANT | | | | |
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. | | |
| X | US 6,221,616 B1 (SALON ET AL) 24 April 2001 (24.04.2001), columns 17-18, starting on line 13. | 1-24 | | |
| X | US 6,221,613 B1 (SALON ET AL) 24 April 2001 (24.04.2001), columns 17-18, starting on line 13. | 1-24 | | |
| X, E | US 6,291,195 B1 (SALON ET AL), 18 September 2001 (18.09.2001), columns 17-18, starting at line 13. | 1-24 | | |
| Y | CHAMBERS ET AL. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature. 15 July 1999, Vol. 400, pages 261-265, see entire reference. | 1-24 | | |
| Y | MACDONALD ET AL. Molecular characterization of the melanin-concentrating hormone/receptor complex: Identification of critical residues involved in binding and activation. Molecular Pharmacology. 2000, Vol. 58, pages 217-225, see entire reference. | 1-24 | | |
| Y | NOTHACKER ET AL. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nature Cell Biology. October 1999, Vol. 1, pages 383-385, see entire reference. | 1-24 | | |
| <input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex. | | | | |
| <table border="0"> <tr> <td style="vertical-align: top;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> </td> </tr> </table> | | | <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> | <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> |
| <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> | <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations being obvious to a person skilled in the art</p> <p>"Z" document member of the same patent family</p> | | | |
| Date of the actual completion of the international search 07 October 2002 (07.10.2002) | | Date of mailing of the international search report 03 JAN 2003 | | |
| Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20531 Facsimile No. 703 305-3230 | | Authorized officer Deborah Reynolds Telephone No. 703 308-1235 | | |

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

PCT/US02/08413

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Y | DROZDZ ET AL. Characterization of the receptor for melanin-concentrating hormone on melanoma cells by photocrosslinking. Annals New York Academy of Sciences, 1999, pages 210-213. | 1-24 |

Form PCT/ISA/210 (second sheet) (July 1998)

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)